Academic Journal
Q2Revue Neurologique
About Revue Neurologique
Revue Neurologique is a scholarly journal published by Elsevier Masson s.r.l.. SCImago 2025 lists it in Q2, with an SJR of 0.757 and H-index of 65.
Coverage: 1946-1947, 1950-1961, 1963-2026. Research categories: Neurology (Q2); Neurology (clinical) (Q2).
Source-backed journal facts
Topics in published research
Peripheral Neuropathies and Disorders; Parkinson's Disease Mechanisms and Treatments; Epilepsy research and treatment; Acute Ischemic Stroke Management; Health, Medicine and Society; Multiple Sclerosis Research Studies.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
3,620.00 USD; 3,300.00 EUR; 2,900.00 GBP; 448,990.00 JPY
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Towards the integration of open-label extension and real-world evidence in ALS therapeutic evaluation?
P. Corcia, A. Erazo, P. Couratier
2026-10 · DOI: 10.1016/j.neurol.2026.09.004The good, the bad, and the ugly: A three-circuit model of Parkinson's tremor
R.C. Helmich, K.R.E van den Berg
2026-10 · DOI: 10.1016/j.neurol.2026.09.003The eyes and Parkinsonian syndromes
B.S. Chen, D.S. Sandlin, V. Biousse
2026-09 · DOI: 10.1016/j.neurol.2026.09.005Neuro-Whipple presenting as autoimmune encephalitis
R. Assaraj, I. Al Chare, C. Marois, C. Bousquet-Mélou et al.
2026-09 · DOI: 10.1016/j.neurol.2026.05.003Autosomal recessive cerebellar ataxia: What have we learnt in the last 30 years?
C. Tranchant
2026-09 · DOI: 10.1016/j.neurol.2026.09.002Multimodal assessment of minimally conscious state and cognitive motor dissociation in neurocritical care: A critical review
B.K. Vitturi
2026-09 · DOI: 10.1016/j.neurol.2026.04.010Current management and treatment of patients with myasthenia gravis in France: A survey of the neurologist's perspective
P. Cintas, E. Salort-Campana, S. Demeret, T. Stanbury et al.
2026-09 · DOI: 10.1016/j.neurol.2026.04.007Editorial Board
2026-09 · DOI: 10.1016/s0035-3787(26)00566-7Trends and regional disparities in triptan dispensing in France between 2014 and 2025: A nationwide open-data study
S. Redon, V. Arcani, A. Donnet
2026-09 · DOI: 10.1016/j.neurol.2026.08.003Continuous subcutaneous perfusion of apomorphine in Parkinson's disease: Towards monotherapy?
A. Marques, C. Lambert, P. Derost, C. Beal et al.
2026-09 · DOI: 10.1016/j.neurol.2026.05.002Progress in PLS: Natural history studies, extra-motor deficits, novel instruments, neuroimaging, epidemiology and genetics
A. Toomey, J. Kleinerova, M. Tahedl, N. Mandal et al.
2026-09 · DOI: 10.1016/j.neurol.2026.07.008Macrophage inclusions in patients undergoing antisense oligonucleotide therapy for ALS or SMA: A retrospective and transversal study
R. Demeret, D. Vieles Marais, E. Treiner, B. Acket et al.
2026-09 · DOI: 10.1016/j.neurol.2026.05.005Novel variants and rare clinical presentations in MFN2-related Charcot-Marie-Tooth disease: Insights from 10 families
H. Gharebaghian, M. Ravanbod, A. Ghasemi, A. Asghar Okhovat et al.
2026-09 · DOI: 10.1016/j.neurol.2026.04.008Contents
2026-09 · DOI: 10.1016/s0035-3787(26)00569-2Cranial nerve III palsy with contralateral peripheral upper-limb involvement in Lyme neuroborreliosis
T. Sinha, H. Khuram, N.S. Streicher
2026-09 · DOI: 10.1016/j.neurol.2026.08.001Effect of levodopa-carbidopa intestinal gel infusion on objective measures of daytime sleepiness and nocturnal sleep in Parkinson's disease
M. Bucy, N. Carpentier, G. Clement, S. Richard et al.
2026-09 · DOI: 10.1016/j.neurol.2026.07.002Geographic disparities in MRI features of ischemic stroke and small vessel disease: A comparative study between French Guiana and mainland France. Findings from the BECATOUR multicenter registry
C. Maisonnier, J.-P. Cottier, G. Charbonnier, A. Monaya et al.
2026-09 · DOI: 10.1016/j.neurol.2026.05.004Comment on: “Neuroimaging confirms selective cerebral involvement in primary lateral sclerosis and predilection to brain regions with high metabolic activity” [Rev Neurol. 182 (2026): 514–27]
FNU Sarah, FNU Sobh
2026-09 · DOI: 10.1016/j.neurol.2026.08.002Access to hospital-based rehabilitation for people with multiple sclerosis in France: A nationwide study (2017–2023)
M. Mainguy, C. Massot, P. Gallien, V. Reynaud et al.
2026-09 · DOI: 10.1016/j.neurol.2026.07.007Real-world assessment of effectiveness and safety of candesartan in migraine prevention: Results of the French FHU InovPain registry
S. Ferrao-Malheiro, R. Fabre, M. Lanteri-Minet
2026-09 · DOI: 10.1016/j.neurol.2026.05.006Reviews
Community Reviews
Version History
October 4, 2026 at 9:06 pm
October 2, 2026